



<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(e))				Docket No. 19413	
In Re Application Of: Ben Croker, et al.					
Application No. 10/559,711	Filing Date December 5, 2005	Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. 3843
Title: <b>METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)</b>					
<p>Address to:  <b>Commissioner for Patents</b>  <b>P.O. Box 1450</b>  <b>Alexandria, VA 22313-1450</b></p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="padding-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					

P10A/REV05

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.98(c))				Docket No. 19413	
In Re Application of: Ben Croker, et al.					
Application No.	Filing Date	Examining Office	Customer No.	Group Art Unit	Confirmation No.
10/559,711	December 5, 2005	Unassigned	23389	Unassigned	3843
Title: <b>METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)</b>					
<b>Payment of Fee</b> (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))					
<input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>19-1013/SSMP</u> as described below.					
<input type="checkbox"/> Charge the amount of _____ <input type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
<b>Certificate of Transmission by Facsimile*</b>			<b>Certificate of Mailing by First Class Mail</b>		
<div style="border: 1px solid black; padding: 5px;"> <p>I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa</p> <p>_____ (Date)</p> <p>_____ Signature</p> <p>_____ Typed or Printed Name of Person Signing Certificate</p> </div>			<div style="border: 1px solid black; padding: 5px;"> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p> <p><u>May 19, 2006</u> (Date)</p> <p> Signature of Person Mailing Correspondence</p> <p>Xiaochun Zhu Typed or Printed Name of Person Mailing Certificate</p> </div>		
<p>*This certificate may only be used if paying by deposit account.</p>					
 Signature			Dated: May 19, 2006		
Xiaochun Zhu Registration No. 56,311 Scully, Scott, Murphy & Presser, P. C. 400 Garden City Plaza-STE 300 Garden City, New York 11530 (516) 742-4343					
cc: XZ:ab					

10559711 *PAU*: 1635**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Ben Croker, et al.	<b>Examiner:</b>	Unassigned
<b>Serial No.:</b>	10/559,711	<b>Art Unit:</b>	Unassigned
<b>Filed:</b>	December 5, 2005	<b>Docket:</b>	19413
<b>For:</b>	<b>Dated:</b>		May 19, 2006
	METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)		

**Confirmation No.:** 3843

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 19, 2006

  
Xiaochun Zhu


1. A. Matsumoto, et al., "A Role of Suppressor of Cytokine Signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated Interleukin 2 Production", *J. Exp. Med.*, 197(4): 425-436 (2003);
2. B. A. Croker, et al., "SOCS3 negatively regulates IL-6 signaling in vivo", *Nature Immunology*, 4(6): 540-545 (2003);
3. P. Georgiades, et al., "vavCre Transgenic Mice: A Tool for Mutagenesis in Hematopoietic and Endothelial Lineages", *Genesis*, 34: 251-256 (2002);
4. M. Hörtner, et al., "Suppressor of Cytokine Signaling-3 Is Recruited to the Activated Granulocyte-Colony Stimulating Factor Receptor and Modulates its Signal Transduction", *The Journal of Immunology*, 169: 1219-1227 (2002);
5. M. H. A. Hermans, et al., "Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells", *Blood*, 101(7): 2584-2590 (2003);
6. B. A. Croker, et al., "SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis", *Immunity*, 20: 153-165 (2004);
7. A. Kimura, et al., "SOCS3 Is a Physiological Negative Regulator for Granulopoiesis and Granulocyte Colony-Stimulating Factor Receptor Signaling", *The Journal of Biological Chemistry*, 279(8): 6905-6910 (2004);
8. Gert-Jan M. Van de Geijn, et al., "Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling", *Journal of Leukocyte Biology*, 76: 237-244 (2004); and
9. Gert-Jan M. Van de Geijn, et al., "G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact", *Blood*, 104(3): 667-674 (2004).

The references were cited in an International Search Report dated August 26, 2004 received from the International Searching Authority. Applicants are submitting copies of the above-cited references. A copy of the Search Report was submitted by

Applicants on December 5, 2005. The relevance of the above-identified references has been described in the Search Report.


Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:ab

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE				<b>Atty. Docket No.</b> 19413		<b>Serial No.</b> 10/559,711	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				<b>Applicants</b> Ben Croker, et al.			
(Use several sheets if necessary)				<b>Filing Date</b> December 5, 2005		<b>Group</b> Unassigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						

		Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
	1. A. Matsumoto, et al., "A Role of Suppressor of Cytokine Signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated Interleukin 2 Production", <i>J. Exp. Med.</i> , 197(4): 425-436 (2003)
	2. B. A. Croker, et al., "SOCS3 negatively regulates IL-6 signaling in vivo", <i>Nature Immunology</i> , 4(6): 540-545 (2003)
	3. P. Georgiades, et al., "vavCre Transgenic Mice: A Tool for Mutagenesis in Hematopoietic and Endothelial Lineages", <i>Genesis</i> , 34: 251-256 (2002)
	4. M. Hörtner, et al., "Suppressor of Cytokine Signaling-3 Is Recruited to the Activated Granulocyte-Colony Stimulating Factor Receptor and Modulates its Signal Transduction", <i>The Journal of Immunology</i> , 169: 1219-1227 (2002)
	5. M. H. A. Hermans, et al., "Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells", <i>Blood</i> , 101(7): 2584-2590 (2003)
	6. B. A. Croker, et al., "SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis", <i>Immunity</i> , 20: 153-165 (2004)
	7. A. Kimura, et al., "SOCS3 Is a Physiological Negative Regulator for Granulopoiesis and Granulocyte Colony-Stimulating Factor Receptor Signaling", <i>The Journal of Biological Chemistry</i> , 279(8): 6905-6910 (2004)
	8. Gert-Jan M. Van de Geijn, et al., "Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling", <i>Journal of Leukocyte Biology</i> , 76: 237-244 (2004)
	9. Gert-Jan M. Van de Geijn, et al., "G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact", <i>Blood</i> , 104(3): 667-674 (2004)

EXAMINER /Dana Shin/	DATE CONSIDERED 06/16/2008
----------------------	----------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/